ClinicaliQ Trial Snapshot
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) — Recruiting • Phase II • NCT06635148.
- Long-term safety follow-up study of a gene therapy injection into the eye for geographic atrophy, a type of age-related macular degeneration.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies. Conditions: Geographic Atrophy, Macular Degeneration Interventions: JNJ-81201887, Sham Procedure Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 274 participants